SCHEMBL6473308

SCHEMBL6473308

CC1(C)CCC(C)(C)c2cc(S(=O)(=O)C=C(Cl)Cl)ccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP26B1 Q9NR63 4/20 0.47
CYP26A1 O43174 6/20 0.44
RXRA P19793 11/20 0.40
RXRB P28702 8/20 0.40
RARB P10826 8/20 0.40
RARG P13631 8/20 0.40
RXRG P48443 6/20 0.40
RARA P10276 6/20 0.40
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
GMNN O75496 1/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
NFKB1 P19838 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1022290 0.77 CYP26B1 (0.50) CYP26B1CYP26A1RXRARXRBRARB
SCHEMBL6472379 0.76 RXRA (0.49) CYP26B1CYP26A1RXRARXRBRARB
SCHEMBL1743105 0.74 CYP26B1 (0.50) CYP26B1CYP26A1RXRARXRBRARB
SCHEMBL6472698 0.70 CYP26B1 (0.47) CYP26B1CYP26A1RXRARXRBRARB
SCHEMBL7723491 0.69 RXRA (0.69) CYP26B1CYP26A1RXRARXRBRARB
SCHEMBL1022234 0.67 RXRA (0.63) CYP26B1CYP26A1RXRARXRBRARB
SCHEMBL16516911 0.66 CYP26B1 (0.77) CYP26B1CYP26A1RXRARXRBRARB
SCHEMBL9822386 0.66 RXRA (0.68) CYP26B1CYP26A1RXRARXRBRARB
SCHEMBL7561241 0.66 RXRA (0.49) CYP26B1CYP26A1RXRARXRBRARB
SCHEMBL7085649 0.65 RARG (0.72) CYP26B1CYP26A1RXRARXRBRARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6921777-B2 Heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-26 US disclosed
US-20030012803-A1 Novel heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-01-16 US disclosed
US-6444709-B1 SKIN DISORDERS; ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2002-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030012803-A1 Novel heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them TYR, CYP1B1, MITF CYP26B1 111/4885CYP26A1 78/4885RXRA 935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.